Vivos Therapeutics Inc (NASDAQ:VVOS) — Market Cap & Net Worth
Market Cap & Net Worth: Vivos Therapeutics Inc (VVOS)
Vivos Therapeutics Inc (NASDAQ:VVOS) has a market capitalization of $9.22 Million ($9.22 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27082 globally and #5380 in its home market, demonstrating a -9.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vivos Therapeutics Inc's stock price $0.81 by its total outstanding shares 11420144 (11.42 Million). Analyse Vivos Therapeutics Inc cash flow conversion to see how efficiently the company converts income to cash.
Vivos Therapeutics Inc Market Cap History: 2020 to 2026
Vivos Therapeutics Inc's market capitalization history from 2020 to 2026. Data shows change from $1.69 Billion to $9.22 Million (-64.82% CAGR).
Index Memberships
Vivos Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #789 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2562 of 3165 |
Weight: Vivos Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Vivos Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vivos Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.26x
Vivos Therapeutics Inc's market cap is 3.26 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.69 Billion | $13.07 Million | -$12.06 Million | 129.14x | N/A |
| 2021 | $642.38 Million | $16.89 Million | -$20.29 Million | 38.04x | N/A |
| 2022 | $114.77 Million | $16.02 Million | -$23.84 Million | 7.16x | N/A |
| 2023 | $142.07 Million | $13.80 Million | -$13.58 Million | 10.29x | N/A |
| 2024 | $48.99 Million | $15.03 Million | -$11.14 Million | 3.26x | N/A |
Competitor Companies of VVOS by Market Capitalization
Companies near Vivos Therapeutics Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Vivos Therapeutics Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #141 globally with a market cap of $155.56 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #208 globally with a market cap of $112.79 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #230 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #236 globally with a market cap of $102.56 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #141 | Abbott Laboratories | NYSE:ABT | $155.56 Billion | $89.46 |
| #208 | Stryker Corporation | NYSE:SYK | $112.79 Billion | $294.73 |
| #230 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #236 | Medtronic PLC | NYSE:MDT | $102.56 Billion | $80.00 |
Vivos Therapeutics Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Vivos Therapeutics Inc's market cap moved from $1.69 Billion to $ 9.22 Million, with a yearly change of -64.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $9.22 Million | -60.25% |
| 2025 | $23.18 Million | -52.68% |
| 2024 | $48.99 Million | -65.51% |
| 2023 | $142.07 Million | +23.78% |
| 2022 | $114.77 Million | -82.13% |
| 2021 | $642.38 Million | -61.93% |
| 2020 | $1.69 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Vivos Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.22 Million USD |
| MoneyControl | $9.22 Million USD |
| MarketWatch | $9.22 Million USD |
| marketcap.company | $9.22 Million USD |
| Reuters | $9.22 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vivos Therapeutics Inc
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring… Read more